Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. Media Center/
  3. Press releases /
  4. Innovative Medicine

Innovative Medicine

Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke

Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline™ Study app on iPhone Study aims to assess whether the Heartline™ Study app on iPhone, and the ECG app and irregular rhythm notification feature on Apple Watch, can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation

Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments

Janssen strengthens collaboration with Biomedical Advanced Research and Development Authority (BARDA) in an effort to stem the threat of the global COVID-19 outbreak

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine

Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic

Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma

· Application is based on positive data from the Phase 3 CANDOR study, which were presented at the 2019 American Society of Hematology Annual Meeting

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU

New data featured in multiple presentations across prostate and bladder cancer treatment portfolio and pipeline including ERLEADA® (apalutamide), niraparib and BALVERSATM (erdafitinib)

Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in India

Program aims to raise awareness and reduce stigma of TB among young people in India, as part of Johnson & Johnson’s 10-year initiative to combat world’s leading infectious disease killer

Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent

In two pivotal Phase 3 trials, SPRAVATO®▼ combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms in patients with major depressive disorder who have current suicidal ideation with intent compared to comprehensive standard of care alone

DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma

· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone · Data selected as a Late-Breaking Abstract at ASH 2019